Ensysce Biosciences Reports Third Quarter 2025 Financial Results

~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~~ Further Program Advancement Supported by Preferred Stock Financing ~ SAN DIEGO, CA / …
Jetzt den vollständigen Artikel lesen